Disclaimer - Please note that the insurance accepted list may not be complete. Prior to scheduling an appointment, please contact the doctors' office to verify their participation in your plan.
| Specialty | Urology |
|---|---|
| Clinical Interests | Bladder Cancer Surgery |
| Bladder Replacement | |
| Prostate Cancer | |
| Prostate Cancer Surgery | |
| Urology | |
| Kidney Cancer Surgery | |
| Languages | Hungarian |
| Russian | |
| Gender | Male |
| Education and Training | MD, Mount Sinai School of Medicine |
| Residency, Urology, Mount Sinai Hospital | |
| Fellowship, Urology Oncology, Mount Sinai Hospital |
| Education and Training | MD, Mount Sinai School of Medicine |
|---|---|
| Residency, Urology, Mount Sinai Hospital | |
| Fellowship, Urology Oncology, Mount Sinai Hospital | |
| Board Certification | Urology |
| Specialty | Urology |
|---|---|
| Clinical Interests | Bladder Cancer Surgery |
| Bladder Replacement | |
| Prostate Cancer | |
| Prostate Cancer Surgery | |
| Urology | |
| Kidney Cancer Surgery | |
| Languages | Hungarian |
| Russian | |
| Board Certification | Urology |
Kirschenbaum A, Pacheco E, Schuval BJ, Levine A. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy. World J Urol 1996; 14(6): 360-2.
Robbins SE, Shu WP, Kirschenbaum A, Levine A, Miniati DN, Liu BC. Bone extracellular matrix induces homeobox proteins independent of androgens: Possible mechanism for androgen independent growth in human prostate cancer. Prostate 1996 Dec; 29(6): 362-70.
Levine A, Wang JP, Ren M, Eliashvili E, Russell DW, Kirschenbaum A. Immunohistochemical localization of steroid 5a-reductase 2 in the human male fetal reproductive tract. J Clin Endocrinol Metab 1996 Jan; 81(1): 384-9.
Levine A, Kirschenbaum A, Gabrilove J. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. Mt Sinai J Med 1997 Jan; 64(1): 20-5.
Liu X, Yao S, Kirschenbaum A, Levine A. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates Bcl-2 expression in LNCaP cells. Cancer Res 1998 Oct 1; 58(19): 4245-9.
Liu X, Kirschenbaum A, Yao S, Stearns ME, Holland J, Claffey K, Levine A. Upregulation of vascular endothelial growth factor by cobalt-induced hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 1999 17(8):687-94.
Kirschenbaum A, Itzkowitz S, Wang JP, Yao S, Eliashvili M, Levine A. MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. Mol Urol 1999; 3(3): 163-8.
Liu X, Kirschenbaum A, Yao S, Lee R, Holland J, Levine A. Inhibition of cyclooxygenase-2 suppresses angiogenesis and growth of prostate cancer in vivo. J Urol 2000 Sep; 164: 820-825.
The Mount Sinai Medical Center is home to an extensive array of top-notch research centers and laboratories, where scientists and researchers work to translate the rapid advances in basic science into the innovative patient care for which we are known.
Participating in Mount Sinai’s clinical trials allows you to take advantage of innovative treatments as we work together to advance the future of medicine.
